Anixa delays CAR-T trial in bid to boost efficacy

cafead

Administrator
Staff member
  • cafead   Dec 13, 2019 at 11:02: AM
via Anixa Biosciences has delayed a planned IND filing by 12 months to buy time to improve its CAR-T candidate. The delay will enable Anixa to perform additional genetic engineering intended to boost the efficacy of the treatment in ovarian cancer.

article source